Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
To evaluate the rate of clinically relevant complications associated with iStent inject placement and stability, as determined at 36 months in the postmarket setting.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
358
Subjects will be implanted with the iStent Injection Micro-Bypass device
Eye Doctors of Arizona, PLLC
Phoenix, Arizona, United States
Wolstan and Goldberg Eye Associates
Torrance, California, United States
Glaucoma Associates of Texas
Dallas, Texas, United States
iStent inject placement and stability
The rate of clinically relevant complications associated with iStent inject placement and stability
Time frame: 36 Months
Sight-threatening adverse events
Rate of occurrence of sight-threatening adverse events
Time frame: 36 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.